| Project/Area Number |
26460444
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
鳥井 郁子 兵庫医科大学, 医学部, 准教授 (70207661)
佐藤 鮎子 兵庫医科大学, 医学部, 講師 (20419823)
篠原 義康 兵庫医科大学, 医学部, 助教 (60723509)
工藤 朝雄 兵庫医科大学, 医学部, ポストドクター (60709781)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 悪性中皮腫 / エピジェネティクス / 細胞増殖 / EZH2 |
|---|
| Outline of Final Research Achievements |
In malignant mesothelioma, EZH2 is highly expressed and BAP1 mutation is observed. Suppression of EZH2 expression in mesothelioma cells by RNA interfering method decreased their proliferation, motility, and tumorigenic ability, but could not induce tumorigenesis even when EZH2 was highly expressed in mesothelial cells. The EZH2 high expression group of malignant mesothelioma patients had a poorer prognosis than the EZH2 low expression group. Although high expression of EZH2 alone is insufficient for tumorigenesis of mesothelial cells, the prognosis of malignant mesothelioma patients is thought to be involved in EZH2-controlled growth and invasion related molecules.
Although BAP1 mutation is considered to be a useful molecular marker for diagnosing epithelioid mesothelioma, further investigation is required on the biological function of BAP1 in malignant mesothelioma.
|
